


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. (withdrawn):** A method of inhibiting~~An inhibitor of~~ IL-6 production comprising administering to a subject in need of treatment an effective amount of, a hydroxamic acid derivative of the formula (I):



wherein, R<sup>1</sup> is

- (a) C1-8 alkyl,
- (b) C2-8 alkenyl,
- (c) C2-8 alkynyl,
- ~~(d) halogen,~~
- ~~(e) nitro,~~
- ~~(f) nitrile,~~
- ~~(g) trifluoromethyl,~~
- ~~(h) trifluoromethoxy,~~
- ~~(i) OR<sup>2</sup>,~~
- ~~(j) SR<sup>2</sup>,~~

- ~~(k)  $\text{NR}^3\text{R}^4$ ;~~
- ~~(l)  $\text{COR}^5$ ;~~
- ~~(m) keto;~~
- ~~(n) Cyc1;~~
- (o) C1-8 alkyl substituted by  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{NR}^3\text{R}^4$ ,  $-\text{COR}^5$  or Cyc1,
- ~~(p)  $\text{SO}_2\text{R}^{10}$ ;~~
- ~~(q)  $\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$ ;~~
- ~~(r) C1-8 alkyl substituted by nitrile,  $\text{SO}_2\text{R}^{10}$  or  $\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$ ;~~
- ~~(s)  $\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ ;~~
- ~~(t)  $\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ ;~~
- (u) C1-8 alkyl substituted by  $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$  or  $-\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ ,
- (v) C2-8 alkenyl substituted by  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{NR}^3\text{R}^4$ ,  $-\text{COR}^5$ , Cyc1, nitrile,  $-\text{SO}_2\text{R}^{10}$ ,  $-\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$ ,  $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$  or  $-\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$  or
- (w) C2-8 alkynyl substituted by  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{NR}^3\text{R}^4$ ,  $-\text{COR}^5$ , Cyc1, nitrile,  $-\text{SO}_2\text{R}^{10}$ ,  $-\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$ ,  $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$  or  $-\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ ,
- $\text{R}^2$  is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,
- $\text{R}^3$  and  $\text{R}^4$  are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,
- $\text{R}^5$  is hydroxy, C1-8 alkyl, C1-8 alkoxy,  $-\text{NR}^6\text{R}^7$  or Cyc1,
- $\text{R}^6$  and  $\text{R}^7$  are each independently hydrogen, C1-8 alkyl or Cyc1,
- $\text{R}^{10}$  is C1-8 alkyl or Cyc1,

Cyc1 is morpholine, piperidine or piperazine~~C3-7 mono carbocyclic ring or 5-7 membered mono cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;~~

R<sup>11</sup> is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

R<sup>12</sup> and R<sup>13</sup> are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

m is ~~0~~ or an integer of 1-5;

ring A is a benzene ring~~C3-15 mono-, bi- or tri carbocyclic ring or 5-18 membered mono-, bi- or tri cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

ring B is a benzene ring~~C5-15 mono-, bi- or tri carbocyclic aryl or 5-18 membered mono-, bi- or tri cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

E is a bond, -CH=CH- or -C≡C-;

R<sup>8</sup> is

- (a) C1-8 alkyl,
- (b) C1-8 alkoxy,
- (c) halogen,
- (d) nitro,
- (e) nitrile,
- (f) trifluoromethyl or
- (g) trifluoromethoxy,


with the proviso that when E is a bond, then, optionally,  $R^1$  and  $R^8$ , taken together, may be ~~optionally~~ C1-4 alkylene;

n is 0 or an integer of 1-5;

$R^9$  is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;


a nontoxic salt thereof or a prodrug thereof, as an active ingredient.

**2. (withdrawn):** The ~~method~~inhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by a compound of the formula (IA):




{wherein,  $R^{14}$  is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meanings as defined in claim 1.}

**3. (withdrawn):** The ~~method~~inhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by comprising a compound of the formula (IB):



{wherein, the all symbols have the same meanings as defined in claim 1.}

4. (currently amended): A hydroxamic acid derivative of the formula (I):



wherein, R<sup>1</sup> is

- (a) C1-8 alkyl,
- (b) C2-8 alkenyl,
- (c) C2-8 alkynyl,
- (d) halogen,
- (e) nitro,
- (f) nitrile,
- (g) trifluoromethyl,
- (h) trifluoromethoxy,
- (i) ~~OR<sup>2</sup>~~,
- (j) ~~SR<sup>2</sup>~~,
- (k) ~~NR<sup>3</sup>R<sup>4</sup>~~,
- (l) ~~COR<sup>5</sup>~~,
- (m) ~~keto~~,
- (n) ~~Cycl~~,
- (o) C1-8 alkyl substituted by -OR<sup>2</sup>, -SR<sup>2</sup>, -NR<sup>3</sup>R<sup>4</sup>, -COR<sup>5</sup> or Cycl,
- (p) ~~SO<sub>2</sub>R<sup>10</sup>~~,

~~(q) O (C1-8 alkylene) OR<sup>11</sup>;~~

~~(r) C1-8 alkyl substituted by nitrile, SO<sub>2</sub>R<sup>10</sup> or O (C1-8 alkylene) OR<sup>11</sup>;~~

~~(s) O (C1-8 alkylene) NR<sup>12</sup>R<sup>13</sup>;~~

~~(t) S (C1-8 alkylene) NR<sup>12</sup>R<sup>13</sup>;~~

(u) C1-8 alkyl substituted by -O-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup>- or -S-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup>,

(v) C2-8 alkenyl substituted by -OR<sup>2</sup>, -SR<sup>2</sup>, -NR<sup>3</sup>R<sup>4</sup>, -COR<sup>5</sup>, Cyc1, nitrile, -SO<sub>2</sub>R<sup>10</sup>, -O-(C1-8 alkylene)-OR<sup>11</sup>, -O-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup> or -S-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup> or

(w) C2-8 alkynyl substituted by -OR<sup>2</sup>, -SR<sup>2</sup>, -NR<sup>3</sup>R<sup>4</sup>, -COR<sup>5</sup>, Cyc1, nitrile, -SO<sub>2</sub>R<sup>10</sup>, -O-(C1-8 alkylene)-OR<sup>11</sup>, -O-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup> or -S-(C1-8 alkylene)-NR<sup>12</sup>R<sup>13</sup>,

R<sup>2</sup> is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R<sup>5</sup> is hydroxyl, C1-8 alkyl, C1-8 alkoxy, -NR<sup>6</sup>R<sup>7</sup> or Cyc1,

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen, C1-8 alkyl or Cyc1,

R<sup>10</sup> is C1-8 alkyl or Cyc1;

Cyc1 is morpholine, piperidine or piperazine~~C3-7 mono-carbocyclic ring or 5-7~~

~~membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;~~

R<sup>11</sup> is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

R<sup>12</sup> and R<sup>13</sup> are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

m is ~~0 or~~ an integer of 1-5;

ring A is a benzene ring~~C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

ring B is a benzene ring~~C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

E is a bond,  $-\text{CH}=\text{CH}-$  or  $-\text{C}\equiv\text{C}-$ ;

$\text{R}^8$  is

- (a) C1-8 alkyl,
- (b) C1-8 alkoxy,
- (c) halogen,
- (d) nitro,
- (e) nitrile,
- (f) trifluoromethyl or
- (g) trifluoromethoxy,

with the proviso that when E is a bond then, optionally,  $\text{R}^1$  and  $\text{R}^8$ , taken together, is C1-4 alkylene~~optionally~~;


n is 0 or an integer of 1-5;

$\text{R}^9$  is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;

~~with the proviso that when E is  $\text{CH}=\text{CH}$  or  $\text{C}=\text{C}$ , ring A is C3-7 monocyclyc ring or 5-7 membered monocyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,~~


a nontoxic salt thereof or a prodrug thereof.

**5. (currently amended):** The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IA):



{wherein,  $\text{R}^{14}$  is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meaning as defined in claim [[1.]] 4.

**6. (currently amended):** The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IB):



{wherein, the all symbols have the same meaning as defined in claim [[1.]] 4.

**7. (currently amended):** The compound described in claim 4, wherein E is a bond ~~and~~  
~~ring A is C3-15 mono-, bi- or tri-cycloeclyc ring.~~

**8. (canceled)**



**9. (currently amended):** The compound described in claim 4, wherein E is  $-\text{CH}=\text{CH}-$  or  $-\text{C}\equiv\text{C}-$  and ring A is C3-7 mono-carbocyclic ring.

**10. (canceled)**

**11. (currently amended):** The compound described in claim 4, which is

~~(1) N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(2) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,~~

~~(3) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,~~

~~(4) N-hydroxy-6-(4-(4-methylphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(5) N-hydroxy-6-(4-(4-methoxyphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(6) N-hydroxy-6-(4-(trans-4-propylcyclohexyl)phenyl)-6-hydroxyhexanamide,~~

~~(7) (R)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(8) (S)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(9) N-hydroxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(10) N-hydroxy-6-(4-(pyridin-4-yl)phenyl)-6-hydroxyhexanamide,~~

~~(11) N-hydroxy-6-(4-(pyridin-3-yl)phenyl)-6-hydroxyhexanamide,~~

~~(12) N-hydroxy-6-(4-(2-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(13) N-hydroxy-6-(4-(3-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(14) N-hydroxy-6-(4-(4-bromophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(15) N-hydroxy-6-(4-(thiophen-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(16) N-hydroxy-6-(4-(furan-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(17) N-hydroxy-6-(4-(1,3-dioxy-2,3-dihydroinden-5-yl)phenyl)-6-hydroxyhexanamide,~~

- (18) ~~N hydroxy 6 (4 (4 methylthiophenyl)phenyl) 6 hydroxyhexanamide,~~
- (19) ~~N hydroxy 6 (4 (naphthalen 1 yl)phenyl) 6 hydroxyhexanamide,~~
- (20) ~~N hydroxy 6 (4 (naphthalen 2 yl)phenyl) 6 hydroxyhexanamide,~~
- (21) ~~N hydroxy 6 (4 (4 acetylphenyl)phenyl) 6 hydroxyhexanamide,~~
- (22) ~~N hydroxy 6 (4 (4 hydroxyphenyl)phenyl) 6 hydroxyhexanamide,~~
- (23) ~~N hydroxy 6 (4 (dibenzofuran 4 yl)phenyl) 6 hydroxyhexanamide,~~
- (24) ~~N hydroxy 6 (4 (2 methoxyphenyl)phenyl) 6 hydroxyhexanamide,~~
- (25) ~~N hydroxy 6 (4 (3 methoxyphenyl)phenyl) 6 hydroxyhexanamide,~~
- (26) ~~N hydroxy 6 (4 (4 trifluoromethylphenyl)phenyl) 6 hydroxyhexanamide,~~
- (27) ~~N hydroxy 6 (4 (4 t butylphenyl)phenyl) 6 hydroxyhexanamide,~~
- (28) ~~(R) N hydroxy 6 [4 (5 methylbenzoxazol 2 yl)phenyl] 6 hydroxyhexanamide,~~
- (29) ~~(R) N hydroxy 6 [4 (benzoxazol 2 yl)phenyl] 6 hydroxyhexanamide,~~
- (30) ~~(R) N hydroxy 6 [4 (2 (4 methylthiophenyl)ethynyl)phenyl] 6 hydroxyhexanamide,~~
- (31) ~~(R) N hydroxy 6 [4 (4 methylthiophenyl)phenyl] 6 hydroxyhexanamide,~~
- (32) ~~(R) N hydroxy 6 [4 (4 (dimethylaminomethyl)phenyl)phenyl] 6-~~  
hydroxyhexanamide,
- (33) ~~N hydroxy 6 (4 (trans 4 butylcyclohexyl)phenyl) 6 hydroxyhexanamide,~~
- (34) ~~N hydroxy 6 (4 (trans 4 hydroxycyclohexyl)phenyl) 6 hydroxyhexanamide,~~
- (35) ~~N hydroxy 6 (4 cyclopentylphenyl) 6 hydroxyhexanamide,~~
- (36) ~~N hydroxy 6 [4 (morpholin 4 yl)phenyl] 6 hydroxyhexanamide,~~
- (37) ~~N hydroxy 6 [3 (4 chlorophenyl)phenyl] 6 hydroxyhexanamide,~~

- ~~(38) N-hydroxy-6-[2-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(39) N-hydroxy-6-[4-((1E)-2-phenylvinyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(40) N-hydroxy-6-[4-((1E)-2-(pyridin-4-yl)vinyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(41) N-hydroxy-6-[4-((1E)-2-(pyridin-2-yl)vinyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(42) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyheptanamide,~~
- ~~(43) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxy-7-octenamide,~~
- ~~(44) N-hydroxy-6-(4-biphenyl)-6-hydroxyheptanamide,~~
- ~~(45) (+) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,~~
- ~~(46) (-) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,~~
- ~~(47) (R) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,~~
- ~~(48) (R) N-hydroxy-6-[4-(4-methylphenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(49) (R) N-hydroxy-6-[4-(3-methylphenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(50) (R) N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~
- ~~(51) (R) N-hydroxy-6-[4-(2-phenylethynyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(52) (R) N-hydroxy-6-[4-(benzothiophen-2-yl)phenyl]-6-hydroxyhexanamide,~~
- ~~(53) (R) N-hydroxy-6-[4-(4-(cyanomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(54) (R) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(55) (R) N-hydroxy-6-[4-(4-propylphenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(56) (R) N-hydroxy-6-[4-(4-biphenyl)phenyl]-6-hydroxyhexanamide,~~
- ~~(57) (R) N-hydroxy-6-[4-(1-methylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,~~
- ~~(58) (R) N-hydroxy-6-[4-(indol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(59) (R) N-hydroxy-6-[4-(4-cyanophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(60) (R) N-hydroxy-6-[4-phenyl-2-methylphenyl]-6-hydroxyhexanamide,~~

~~(61) (R) N-hydroxy-6-(4-cycloheptylphenyl)-6-hydroxyhexanamide,~~

~~(62) (R) N-hydroxy-6-(9,10-dihydrophenanthren-2-yl)-6-hydroxyhexanamide,~~

~~(63) (R) N-hydroxy-6-[4-(1-ethoxycarbonylpiperidin-4-yl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(64) (R) N-hydroxy-6-[4-(4-(N-methylcarbamoyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(65) (R) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,~~

~~(66) (R) N-hydroxy-6-[4-(5-hydroxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(67) (R) N-hydroxy-6-[4-(2-(4-methylphenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(68) (R) N-hydroxy-6-[4-((1E)-2-(4-methylphenyl)vinyl)phenyl]-6-hydroxyhexanamide,~~

~~(69) (R) N-hydroxy-6-[4-(4-trifluoromethoxyphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(70) (R) N-hydroxy-6-[4-(4-ethylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(71) (R) N-hydroxy-6-[4-(4-methoxyphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(72) (R) N-hydroxy-6-[4-(4-(1-methylethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(73) (R) N-hydroxy-6-[4-(4-(N,N-dimethylcarbamoylmethyl)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(74) (R) N-hydroxy-6-[4-(benzothiazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(75) (R) N-hydroxy-6-[4-(4-(methoxymethoxymethyl)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(76) (R) N-hydroxy-6-[4-(6-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(77) (R) N-hydroxy-6-[4-(6-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(78) (R) N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(79) (R) N-hydroxy-6-[4-(5-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(80) (R) N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(81)(1) (R)-N-hydroxy-6-[4-(4-(piperidin-1-ylmethyl)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(82) (R) N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(83) (R) N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(84) (R) N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(85) (R) N-hydroxy-6-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(86) (R) N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(87) (R) N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(88) (R) N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(89) (R) N-hydroxy-6-[4-(4-(2-(diethylamino)ethyl)phenyl)phenyl]-6-~~

~~hydroxyhexanamide,~~

~~(90) (R) N-hydroxy-6-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(91) (S) N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(92) (S) N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

- ~~(93) (S) N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;~~
- ~~(94) (S) N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;~~
- ~~(95) (S) N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-~~  
hydroxyhexanamide,
- ~~(96)(2) (R)-N-hydroxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-~~  
hydroxyhexanamide,
- ~~(97) (R) N-hydroxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-~~  
hydroxyhexanamide,
- ~~(98) (R) N-hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide;~~
- ~~(99) (R) N-hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide;~~
- ~~(100) (R) N-hydroxy-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanamide;~~
- ~~(101) (R) N-hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide;~~
- ~~(102) (R) N-hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide;~~
- ~~(103) (R) N-hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide;~~
- ~~(104)(3) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-~~  
hydroxyhexanamide,
- ~~(105)(4) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-~~  
hydroxyhexanamide
- or a nontoxic salt thereof.

**12. (currently amended)** The compound described in claim 5, which is:

~~(1) N-(1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-~~  
hydroxyhexanamide,

~~(2) N-(1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-~~  
hydroxyhexanamide,

~~(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-~~  
hydroxyhexanamide,

~~(4) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-~~  
hydroxyhexanamide,

~~(5) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-~~  
hydroxyhexanamide,

~~(6) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-~~  
hydroxyhexanamide,

~~(7) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-~~  
6-hydroxyhexanamide,

~~(8)~~(1) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(morpholin-4-  
ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

~~(9) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-~~  
hydroxyhexanamide,

~~(10) N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~

Amendment Under 37 C.F.R. § 1.111  
U.S. Serial No. 10/088,832

~~(11)~~(2) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

~~(12)~~(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,

or a nontoxic salt thereof.

**13. (Canceled)**